Sign Out
Advanced mycosis fungoides, Histiocytic lymphoma, Hodgkin's disease, Kaposi's sarcoma, Langerhans cell histiocytosis, Lymphocytic lymphoma, Renal cell carcinoma, Testicular cancer
Adult: Alone or in combination with other antineoplastic agents: Approx 6 mg/m2, administered not more often than once every 7 days. Alternatively, initiate with a single dose of 3.7 mg/m2, then increased at weekly intervals in increments of approx 1.8 mg/m2 based on patient’s WBC count until the desired therapeutic response is reached. Usual dose: 5.5-7.4 mg/m2 once every 7 days. Max: 18.5 mg/m2 once every 7 days. Doses are given not more frequently than once every 7 days via infusion over 5-10 minutes or inj over 1 minute into the tubing of a running IV infusion. Do not increase dose if leucocyte count is reduced to approx 3,000 cells/mm3; administer the Max dose that does not cause leucopenia at weekly intervals for maintenance. Do not administer the next dose, even if 7 days have elapsed unless the WBC count has returned to at least 4,000 cells/mm3. Dosage and treatment protocol recommendations may vary among individual products and between countries (refer to detailed product and local treatment guidelines).
Child: Dose is individualised based on the disease being treated, schedule used, and whether given as a single agent or part of a combination chemotherapy regimen. Usual dose: Approx 6 mg/m2, administered not more often than once every 7 days. Alternatively, initiate with a single dose of 2.5 mg/m2, then increased at weekly intervals in increments of approx 1.25 mg/m2 based on patient’s WBC count until the desired therapeutic response is reached. Max: 12.5 mg/m2 once every 7 days. Doses are given not more frequently than once every 7 days via infusion over 5-10 minutes or inj over 1 minute into the tubing of a running IV infusion. Do not increase dose if leucocyte count is reduced to approx 3,000 cells/mm3; administer the Max dose that does not cause leucopenia at weekly intervals for maintenance. Do not administer the next dose, even if 7 days have elapsed unless the WBC count has returned to at least 4,000 cells/mm3. Dosage and treatment protocol recommendations may vary among individual products and between countries (refer to detailed product and local treatment guidelines).
Child: Dose is individualised based on the disease being treated, schedule used, and whether given as a single agent or part of a combination chemotherapy regimen. Usual dose: Approx 6 mg/m2, administered not more often than once every 7 days. Alternatively, initiate with a single dose of 2.5 mg/m2, then increased at weekly intervals in increments of approx 1.25 mg/m2 based on patient’s WBC count until the desired therapeutic response is reached. Max: 12.5 mg/m2 once every 7 days. Doses are given not more frequently than once every 7 days via infusion over 5-10 minutes or inj over 1 minute into the tubing of a running IV infusion. Do not increase dose if leucocyte count is reduced to approx 3,000 cells/mm3; administer the Max dose that does not cause leucopenia at weekly intervals for maintenance. Do not administer the next dose, even if 7 days have elapsed unless the WBC count has returned to at least 4,000 cells/mm3. Dosage and treatment protocol recommendations may vary among individual products and between countries (refer to detailed product and local treatment guidelines).
Intravenous
Choriocarcinoma
Adult: For cases resistant to other chemotherapeutic agents: Alone or in combination with other antineoplastic agents: Approx 6 mg/m2, administered not more often than once every 7 days. Alternatively, initiate with a single dose of 3.7 mg/m2, then increased at weekly intervals in increments of approx 1.8 mg/m2 based on patient’s WBC count until the desired therapeutic response is reached. Usual dose: 5.5-7.4 mg/m2 once every 7 days. Max: 18.5 mg/m2 once every 7 days. Doses are given not more frequently than once every 7 days via infusion over 5-10 minutes or inj over 1 minute into the tubing of a running IV infusion. Do not increase dose if leucocyte count is reduced to approx 3,000 cells/mm3; administer the Max dose that does not cause leucopenia at weekly intervals for maintenance. Do not administer the next dose, even if 7 days have elapsed unless the WBC count has returned to at least 4,000 cells/mm3. Dosage and treatment protocol recommendations may vary among individual products and between countries (refer to detailed product and local treatment guidelines).
Child: Dose is individualised based on the disease being treated, schedule used, and whether given as a single agent or part of a combination chemotherapy regimen. Usual dose: Approx 6 mg/m2, administered not more often than once every 7 days. Alternatively, initiate with a single dose of 2.5 mg/m2, then increased at weekly intervals in increments of approx 1.25 mg/m2 based on patient’s WBC count until the desired therapeutic response is reached. Max: 12.5 mg/m2 once every 7 days. Doses are given not more frequently than once every 7 days via infusion over 5-10 minutes or inj over 1 minute into the tubing of a running IV infusion. Do not increase dose if leucocyte count is reduced to approx 3,000 cells/mm3; administer the Max dose that does not cause leucopenia at weekly intervals for maintenance. Do not administer the next dose, even if 7 days have elapsed unless the WBC count has returned to at least 4,000 cells/mm3. Dosage and treatment protocol recommendations may vary among individual products and between countries (refer to detailed product and local treatment guidelines).
Child: Dose is individualised based on the disease being treated, schedule used, and whether given as a single agent or part of a combination chemotherapy regimen. Usual dose: Approx 6 mg/m2, administered not more often than once every 7 days. Alternatively, initiate with a single dose of 2.5 mg/m2, then increased at weekly intervals in increments of approx 1.25 mg/m2 based on patient’s WBC count until the desired therapeutic response is reached. Max: 12.5 mg/m2 once every 7 days. Doses are given not more frequently than once every 7 days via infusion over 5-10 minutes or inj over 1 minute into the tubing of a running IV infusion. Do not increase dose if leucocyte count is reduced to approx 3,000 cells/mm3; administer the Max dose that does not cause leucopenia at weekly intervals for maintenance. Do not administer the next dose, even if 7 days have elapsed unless the WBC count has returned to at least 4,000 cells/mm3. Dosage and treatment protocol recommendations may vary among individual products and between countries (refer to detailed product and local treatment guidelines).
Intravenous
Breast carcinoma
Adult: For cases unresponsive to appropriate endocrine surgery and hormonal therapy: Alone or in combination with other antineoplastic agents: Approx 6 mg/m2, administered not more often than once every 7 days. Alternatively, initiate with a single dose of 3.7 mg/m2, then increased at weekly intervals in increments of approx 1.8 mg/m2 based on patient’s WBC count until the desired therapeutic response is reached. Usual dose: 5.5-7.4 mg/m2 once every 7 days. Max: 18.5 mg/m2 once every 7 days. Doses are given not more frequently than once every 7 days via infusion over 5-10 minutes or inj over 1 minute into the tubing of a running IV infusion. Do not increase dose if leucocyte count is reduced to approx 3,000 cells/mm3; administer the Max dose that does not cause leucopenia at weekly intervals for maintenance. Do not administer the next dose, even if 7 days have elapsed unless the WBC count has returned to at least 4,000 cells/mm3. Dosage and treatment protocol recommendations may vary among individual products and between countries (refer to detailed product and local treatment guidelines).
Child: Dose is individualised based on the disease being treated, schedule used, and whether given as a single agent or part of a combination chemotherapy regimen. Usual dose: Approx 6 mg/m2, administered not more often than once every 7 days. Alternatively, initiate with a single dose of 2.5 mg/m2, then increased at weekly intervals in increments of approx 1.25 mg/m2 based on patient’s WBC count until the desired therapeutic response is reached. Max: 12.5 mg/m2 once every 7 days. Doses are given not more frequently than once every 7 days via infusion over 5-10 minutes or inj over 1 minute into the tubing of a running IV infusion. Do not increase dose if leucocyte count is reduced to approx 3,000 cells/mm3; administer the Max dose that does not cause leucopenia at weekly intervals for maintenance. Do not administer the next dose, even if 7 days have elapsed unless the WBC count has returned to at least 4,000 cells/mm3. Dosage and treatment protocol recommendations may vary among individual products and between countries (refer to detailed product and local treatment guidelines).
Child: Dose is individualised based on the disease being treated, schedule used, and whether given as a single agent or part of a combination chemotherapy regimen. Usual dose: Approx 6 mg/m2, administered not more often than once every 7 days. Alternatively, initiate with a single dose of 2.5 mg/m2, then increased at weekly intervals in increments of approx 1.25 mg/m2 based on patient’s WBC count until the desired therapeutic response is reached. Max: 12.5 mg/m2 once every 7 days. Doses are given not more frequently than once every 7 days via infusion over 5-10 minutes or inj over 1 minute into the tubing of a running IV infusion. Do not increase dose if leucocyte count is reduced to approx 3,000 cells/mm3; administer the Max dose that does not cause leucopenia at weekly intervals for maintenance. Do not administer the next dose, even if 7 days have elapsed unless the WBC count has returned to at least 4,000 cells/mm3. Dosage and treatment protocol recommendations may vary among individual products and between countries (refer to detailed product and local treatment guidelines).
